These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2804374)

  • 21. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
    Miller JS; Verfaillie C; McGlave P
    Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
    Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
    Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.
    Zhai YF; Esselman WJ; Oakley CS; Chang CC; Welsch CW
    Cancer Immunol Immunother; 1992; 35(4):237-45. PubMed ID: 1511458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. rIL-4 differentially regulates rIL-2-induced murine NK and LAK killing in CD8+ and CD8- precursor cell subsets.
    Merrow MW; Huber BT
    Int Immunol; 1991 Jun; 3(6):551-61. PubMed ID: 1909562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma.
    Anderson PM; Bach FH; Ochoa AC
    Cancer Immunol Immunother; 1988; 27(1):82-8. PubMed ID: 3260824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells.
    Wallgren A; Festin R; Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
    Blood; 1993 Aug; 82(4):1230-8. PubMed ID: 8102559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
    Treichel RS; Olken S
    Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Target cell-induced apoptosis of interleukin-2-activated human natural killer cells: roles of cell surface molecules and intracellular events.
    Yamauchi A; Taga K; Mostowski HS; Bloom ET
    Blood; 1996 Jun; 87(12):5127-35. PubMed ID: 8652825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
    J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy.
    Gottlieb DJ; Prentice HG; Heslop HE; Bello-Fernandez C; Bianchi AC; Galazka AR; Brenner MK
    Blood; 1989 Nov; 74(7):2335-42. PubMed ID: 2804369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural killer (NK) and lymphokine-activated killer (LAK) activities in a patient who recovered from cancer, and the characteristics of LAK cells generated from CD4-CD8- and CD8+ peripheral blood lymphocytes.
    Komatsu F; Kihara K
    Clin Immunol Immunopathol; 1995 Oct; 77(1):75-81. PubMed ID: 7554487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human lymphokine-activated killer (LAK) cells: III. Effect of L-phenylalanine methyl ester on LAK cell activation from human peripheral blood mononuclear cells: possible protease involvement of monocytes, natural killer cells and LAK cells.
    Leung KH
    Cancer Immunol Immunother; 1991; 34(1):31-6. PubMed ID: 1760808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia.
    Verfaillie C; Kay N; Miller W; McGlave P
    Blood; 1990 Jul; 76(2):401-8. PubMed ID: 1695114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blocking of MHC class I antigens on leukemic B-cells enhances their conjugate formation with cytotoxic lymphocytes and their susceptibility to lysis.
    Palucka KA; Reizenstein P; Ost A; Porwit-MacDonald A
    Leuk Lymphoma; 1998 Feb; 28(5-6):573-81. PubMed ID: 9613988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
    Grant AJ; Merchant RE; Hall RE
    Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of murine lymphokine-activated killer cells by recombinant IL-7.
    Lynch DH; Miller RE
    J Immunol; 1990 Sep; 145(6):1983-90. PubMed ID: 1975262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
    Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-gamma in oral cancer patients.
    Yoneda K; Yamamoto T; Ueta E; Osaki T
    J Clin Immunol; 1992 Jul; 12(4):289-99. PubMed ID: 1512302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.